[1]
|
Smith, C.I.E., Backesjo, C.M., Berglof, A., et al. (1998) X-Linked Agammaglobulinemia: Lack of Mature B Lineage Cells Caused by Mutations in the Btk Kinase. Springer Seminars in Immunopathology, 19, 369-381.
https://doi.org/10.1007/BF00792597
|
[2]
|
Mohamed, A.J., Yu, L., Backesjo, C.M., et al. (2009) Bruton’s Tyro-sine Kinase (Btk): Function, Regulation, and Transformation with Special Emphasis on the PH Domain. Immunological Reviews, 228, 58-73.
https://doi.org/10.1111/j.1600-065X.2008.00741.x
|
[3]
|
Fasano, S. and Isenberg, D.A. (2019) Present and Novel Biologic Drugs in Primary Sjögren’s Syndrome. Clinical and Experimental Rheumatology, 37, S167-S174.
|
[4]
|
Kinnunen, T., Chamberlain, N., Morbach, H., et al. (2013) Specific Peripheral B Cell Tolerance De-fects in Patients with Multiple Sclerosis. Journal of Clinical Investigation, 123, 2737-2741.
|
[5]
|
Di Paolo, J.A., Huang, T., Balazs, M., et al. (2011) Specific Btk Inhibition Suppresses B Cell- and Myeloid Cell-Mediated Arthritis. Nature Chemical Biology, 7, 41-50. https://doi.org/10.1038/nchembio.481
|
[6]
|
Roschewski, M., Lionakis, M.S., Sharman, J.P., et al. (2020) Inhibition of Bruton Tyrosine Kinase in Patients with Severe COVID-19. Science Immunology, 5, eabd0110. https://doi.org/10.1126/sciimmunol.abd0110
|
[7]
|
Akinleye, A., Chen, Y., Mukhi, N., et al. (2013) Ib-rutinib and Novel BTK Inhibitors in Clinical Development. Journal of Hematology & Oncology, 6, Article No. 59. https://doi.org/10.1186/1756-8722-6-59
|
[8]
|
Burger, J.A. and Wiestner, A. (2018) Targeting B Cell Receptor Signalling in Cancer: Preclinical and Clinical Advances. Nature Reviews Cancer, 18, 148-167. https://doi.org/10.1038/nrc.2017.121
|
[9]
|
Nimmerjahn, F. and Ravetch, J.V. (2008) Fcγ Receptors as Regulators of Immune Responses. Nature Reviews Immunology, 8, 34-47.
|
[10]
|
Hata, D., Kawakami, Y., Inagaki, N., et al. (1998) Involvement of Bruton’s Tyrosine Kinase in FcεRI-Dependent Mast Cell Degranulation and Cytokine Production. Jour-nal of Experimental Medicine, 187, 1235-1247.
https://doi.org/10.1084/jem.187.8.1235
|
[11]
|
Smiljkovic, D., Blatt, K., Stefanzl, G., et al. (2017) BTK Inhibition Is a Potent Approach to Block IgE-Mediated Histamine Release in Human Basophils. Allergy, 72, 1666-1676. https://doi.org/10.1111/all.13166
|
[12]
|
Takeuchi, O. and Akira, S. (2010) Pattern Recognition Receptors and In-flammation. Cell, 140, 805-820.
https://doi.org/10.1016/j.cell.2010.01.022
|
[13]
|
Rawlings, D.J., Schwartz, M.A., Jackson, S.W., et al. (2012) Inte-gration of B Cell Responses through Toll-Like Receptors and Antigen Receptors. Nature Reviews Immunology, 12, 282-294. https://doi.org/10.1038/nri3190
|
[14]
|
Katewa, A., Wang, Y.G., Hackney, J.A., et al. (2017) Btk-Specific Inhibition Blocks Pathogenic Plasma Cell Signatures and Myeloid Cell-Associated Damage in IFNα-Driven Lupus Ne-phritis. JCI Insight, 2, e90111.
|
[15]
|
Liclican, A., Serafini, L., Xing, W., et al. (2020) Biochemical Characterization of Tirabrutinib and Other Irreversible Inhibitors of Bruton’s Tyrosine Kinase Reveals Differences in On- and Off-Target In-hibition. Biochimica et Biophysica Acta (BBA)—General Subjects, 1864, Article ID: 129531. https://doi.org/10.1016/j.bbagen.2020.129531
|
[16]
|
Owens, T. (2018) Discovery of PRN1008: A Reversible Co-valent BTK Inhibitor for Treatment of Autoimmune Diseases. Proceedings of the 255th American Chemical Society Na-tional Meeting & Exposition, New Orleans, 18-22 March 2018.
|
[17]
|
Smith, P.F., Krishnarajah, J., Nunn, P.A., et al. (2017) A Phase I Trial of PRN1008, a Novel Reversible Covalent Inhibitor of Bruton’s Tyrosine Kinase, in Healthy Volunteers. British Journal of Clinical Pharmacology, 83, 2367-2376.
https://doi.org/10.1111/bcp.13351
|
[18]
|
Barf, T., Covey, T., Izumi, R., et al. (2017) Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and in Vivo Potency Profile. Journal of Pharmacology and Experimental Therapeutics, 363, 240-252. https://doi.org/10.1124/jpet.117.242909
|
[19]
|
Treon, S.P., Tripsas, C.K., Meid, K., et al. (2015) Ibrutinib in Previously Treated Waldenstrm’s Macroglobulinemia. New Eng-land Journal of Medicine, 372, 1430-1440. https://doi.org/10.1056/NEJMoa1501548
|
[20]
|
Yoshizawa, T., Ariza, Y., Ueda, Y., et al. (2012) Development of a Bruton’s Tyrosine Kinase (BTK) Inhibitor, ONO-4059: Efficacy in a Col-lagen Induced Arthritis (CIA) Model Indicates Potential Treatment for Rheumatoid Arthritis (RA). Arthritis and Rheu-matism, 64, S709-S.
|
[21]
|
Burger, J.A. (2014) Bruton’s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials. Current Hematologic Malignancy Reports, 9, 44-49. https://doi.org/10.1007/s11899-013-0188-8
|
[22]
|
Dhillon, S. (2020) Tirabrutinib: First Approval. Drugs, 80, 835-840. https://doi.org/10.1007/s40265-020-01318-8
|
[23]
|
Zhang, B., Zhao, R.B., Liang, R.X., et al. (2020) Abstract CT132: Orelabrutinib, a Potent and Selective Bruton’s Tyrosine Kinase Inhibitor with Superior Safety Profile and Excellent PK/PD Properties. Proceedings of the AACR Annual Meeting 2020, Philadelphia, PA, 27-28 April 2020 and 22-24 June 2020.
https://doi.org/10.1158/1538-7445.AM2020-CT132
|
[24]
|
Dahl, K., Turner, T. and Vasdev, N. (2020) Radiosyn-thesis of a Bruton’s Tyrosine Kinase Inhibitor, [11C]Tolebrutinib, via Palladium-NiXantphos-Mediated Carbonylation. Journal of Labelled Compounds and Radiopharmaceuticals, 63, 482-487. https://doi.org/10.1002/jlcr.3872
|
[25]
|
Zhao, D., Huang, S.S., Qu, M.H., et al. (2017) Structural Optimization of Diphenylpyrimidine Derivatives (DPPYs) as Potent Bruton’s Tyrosine Kinase (BTK) Inhibitors with Improved Activity toward B Leukemia Cell Lines. European Journal of Medicinal Chemistry, 126, 444-455. https://doi.org/10.1016/j.ejmech.2016.11.047
|
[26]
|
Evans, E.K., Tester, R., Aslanian, S., et al. (2013) Inhibition of Btk with CC-292 Provides Early Pharmacodynamic Assessment of Activity in Mice and Humans. Journal of Pharma-cology and Experimental Therapeutics, 346, 219-228.
https://doi.org/10.1124/jpet.113.203489
|
[27]
|
Caldwell, R.D., Qiu, H., Askew, B.C., et al. (2019) Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treat-ment of Immunological Diseases. Journal of Medicinal Chemistry, 62, 7643-7655. https://doi.org/10.1021/acs.jmedchem.9b00794
|
[28]
|
Angst, D., Gessier, F., Janser, P., et al. (2020) Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton’s Tyrosine Kinase. Journal of Me-dicinal Chemistry, 63, 5102-5118.
https://doi.org/10.1021/acs.jmedchem.9b01916
|
[29]
|
Liu, Q., Batt, D.G., Chaudhry, C., et al. (2018) Conversion of Carbazole Carboxamide Based Reversible Inhibitors of Bruton’s Tyrosine Kinase (BTK) into Potent, Selective Irreversi-ble Inhibitors in the Carbazole, Tetrahydrocarbazole, and a New 2,3-Dimethylindole Series. Bioorganic & Medicinal Chemistry Letters, 28, 3080-3084.
https://doi.org/10.1016/j.bmcl.2018.07.041
|
[30]
|
Watterson, S.H., Liu, Q., Bertrand, M.B., et al. (2019) Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK). Journal of Medicinal Chemistry, 62, 3228-3250. https://doi.org/10.1021/acs.jmedchem.9b00167
|
[31]
|
Young, W.B., Barbosa, J., Blomgren, P., et al. (2015) Potent and Selective Bruton’s Tyrosine Kinase Inhibitors: Discovery of GDC-0834. Bioorganic & Medicinal Chemistry Letters, 25, 1333-1337.
https://doi.org/10.1016/j.bmcl.2015.01.032
|
[32]
|
Hopkins, B.T., Bame, E., Bajrami, B., et al. (2021) Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis. Journal of Medicinal Chemistry, 65, 1206-1224.
|
[33]
|
Liu, J., Guiadeen, D., Krikorian, A., et al. (2020) Potent, Non-Covalent Reversible BTK Inhibitors with 8-Amino- Imidazo[1,5-a] Pyrazine Core Featuring 3-Position Bicyclic Ring Substitutes. Bioorganic & Medicinal Chemistry Letters, 30, Article ID: 127390. https://doi.org/10.1016/j.bmcl.2020.127390
|
[34]
|
Smith, C.R., Dougan, D.R., Komandla, M., et al. (2015) Frag-ment-Based Discovery of a Small Molecule Inhibitor of Bruton’s Tyrosine Kinase. Journal of Medicinal Chemistry, 58, 5437-5444.
https://doi.org/10.1021/acs.jmedchem.5b00734
|
[35]
|
Yao, X., Sun, X.Y., Jin, S.Y., et al. (2019) Discovery of 4-Aminoquinoline-3-Carboxamide Derivatives as Potent Reversible Bruton’s Tyrosine Kinase Inhibitors for the Treat-ment of Rheumatoid Arthritis. Journal of Medicinal Chemistry, 62, 6561-6574. https://doi.org/10.1021/acs.jmedchem.9b00329
|
[36]
|
Wang, X.J., Barbosa, J., Blomgren, P., et al. (2017) Discov-ery of Potent and Selective Tricyclic Inhibitors of Bruton’s Tyrosine Kinase with Improved Druglike Properties. ACS Medicinal Chemistry Letters, 8, 608-613.
https://doi.org/10.1021/acsmedchemlett.7b00103
|
[37]
|
Crawford, J.J.Y., Johnson, A.R., Misner, D.L., et al. (2018) Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton’s Tyrosine Kinase Inhibitor in Early Clinical De-velopment. Journal of Medicinal Chemistry, 61, 2227- 2245. https://doi.org/10.1021/acs.jmedchem.7b01712
|
[38]
|
Cohen, S., Tuckwell, K., Katsumoto, T.R., et al. (2020) Fenebrutinib versus Placebo or Adalimumab in Rheumatoid Arthritis: A Randomized, Double-Blind, Phase II Trial. Ar-thritis & Rheumatology, 72, 1435-1446.
https://doi.org/10.1002/art.41275
|
[39]
|
Zhang, D.T., Gong, H. and Meng, F.C. (2021) Recent Advances in BTK Inhibitors for the Treatment of Inflammatory and Autoimmune Diseases. Molecules, 26, Article No. 4907. https://doi.org/10.3390/molecules26164907
|